Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece
Semaglutide 2.4 mg is likely to be a cost-effective treatment option compared to liraglutide 3 mg for patients with a BMI ≥ 35 and at least one weight-related comorbidity in Greece.
Authors
- Panagiotis Papantoniou (ORCID: https://orcid.org/0000-0001-5384-4918)
- N Maniadakis (ORCID: https://orcid.org/0000-0002-4103-4181)
Institutions
- University of West Attica (GR)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-10-28
- DOI
- https://doi.org/10.3389/fpubh.2025.1690211
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- University of West Attica